- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04229628
Hypertension and Diabetes Mellitus Community Management Center(HAD-COME) Project
January 12, 2020 updated by: Guangdong Provincial People's Hospital
Establishment of Hypertension and Diabetes Mellitus Community Management Center(HAD-COME) Project
To develop and implement quality improvement programs for the treatment and management of hypertension and diabetes,and preventing and controlling hypertension and diabetes-related diseases in Chinese community.
This program will use data collection, analysis, feedback, and process improvement to extend the use of evidence-based guidelines throughout the healthcare system and improve patient care of hypertension and diabetes in Chinese community.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The aim of this project was to improving care for hypertension and diabetes mellitus in Chinese community.
Study population including subjects who are hypertension and/or diabetes mellitus, of any race or ethnicity, any age.
Study Type
Observational
Enrollment (Anticipated)
100000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Feng Ying-qing, PhD
- Phone Number: +862083827812
- Email: 651792209@qq.com
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510080
- Recruiting
- Guangdong Provincial People's Hospital
-
Contact:
- FENG Yi ng-qing, PhD
- Phone Number: +862083827812
- Email: 651792209@qq.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Hypertension Diabetes mellitus
Description
Inclusion Criteria:
- In accordance with the diagnosis of essential hypertension;
- In accordance with the diagnosis of type 2 diabetes mellitus.
Exclusion Criteria:
- Non-type 2 diabetes patients
- Secondary hypertension
- Non-hypertensive patients
- Type 1 diabetes or other types of diabetes
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of community hypertension patients receiving treatment as Chinese guideline recommended
Time Frame: at the time of enrollment
|
Proportion of community hypertension patients receiving treatment as Chinese guideline recommended at the time of enrollment
|
at the time of enrollment
|
Proportion of community diabetes mellitus patients receiving treatment as Chinese guideline recommended
Time Frame: at the time of enrollment
|
Proportion of community diabetes mellitus patients receiving treatment as Chinese guideline recommended at the time of enrollment
|
at the time of enrollment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Feng Ying-qing, PhD, Guangdong Provincial People's Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2020
Primary Completion (Anticipated)
December 31, 2020
Study Completion (Anticipated)
December 31, 2023
Study Registration Dates
First Submitted
January 12, 2020
First Submitted That Met QC Criteria
January 12, 2020
First Posted (Actual)
January 18, 2020
Study Record Updates
Last Update Posted (Actual)
January 18, 2020
Last Update Submitted That Met QC Criteria
January 12, 2020
Last Verified
December 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019364H(R1)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Addpharma Inc.Completed
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedHypertension, Resistant to Conventional Therapy | Primary HypertensionChina
Clinical Trials on No special intervention
-
Centre Hospitalier Intercommunal CreteilCompletedCOVID-19 | Pneumonia, ViralFrance
-
Hopital Louis PradelCompletedCirculatory FailureFrance
-
Hopital Louis PradelCompletedCirculatory FailureFrance
-
Zhejiang UniversityTaizhou HospitalUnknownHypertension | Diabetes | Hyperlipidemia | Vascular DiseaseChina
-
San Diego State UniversityCompletedType 2 Diabetes Mellitus | Atherosclerosis | Hypercholesterolemia | Heart Disease | High Blood PressureUnited States
-
University of North Carolina, Chapel HillCenters for Disease Control and Prevention; Davidson County Health Department; Forsyth County Health Department and other collaboratorsCompletedObesity | Cardiovascular Disease | OverweightUnited States
-
Sun Yat-sen UniversityCompleted
-
University of North Carolina, Chapel HillCenters for Disease Control and PreventionCompleted
-
Richard Solomon MD, PlcNational Institute of Mental Health (NIMH); Michigan State UniversityCompletedAutism Spectrum Disorder | AutismUnited States